Search results for "Lercanidipine"

showing 2 items of 2 documents

Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension

2000

To investigate the efficacy and tolerability of lercanidipine, used as monotherapy once a day, in elderly patients with isolated systolic hypertension (ISH), 83 patients were enrolled in this multicenter, double-blind, randomized, placebo-controlled study. All patients were older than 60 years, and their mean age was 66.7 +/- 5.4 years. ISH was defined as SBPor = 160 mmHg, and DBP95 mmHg. After wash-out and placebo run-in periods, patients were randomly assigned to placebo or lercanidipine (10 mg once a day) treatment for 4 weeks. Non-responding patients of the lercanidipine-treated group were later treated with 20 mg of lercanidipine once a day for 4 additional weeks. At the end of the stu…

MaleAgingDihydropyridinesSystoleBlood PressurePlaceboPlacebo groupOrthostatic vital signsDouble-Blind MethodDiastoleHeart ratemedicineHumansAntihypertensive AgentsAgedbusiness.industryLercanidipineMiddle AgedBlood pressureTreatment OutcomeTolerabilityAnesthesiaIsolated systolic hypertensionHypertensionFemaleGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Long-term effects of lercanidipine on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension

1999

Abstract The goal of this multicenter, randomized, double-masked, parallel- group study was to assess the effects of lercanidipine versus those of hydrochlorothiazide (HCTZ) on the lipoprotein and apolipoprotein profile of patients with mild-to-moderate essential hypertension. After a 2-week washout period, 52 patients (age range, 18 to 70 years) were randomly allocated to receive lercanidipine 10 mg (n = 26) or HCTZ 12.5 mg (n = 26) once a day for 24 weeks. In nonresponding patients, the dose was increased to 20 or 30 mg of lercanidipine once a day and to 25 or 37.5 mg of HCTZ once a day, after 4 and 8 weeks, respectively. To assess long-term effects, patients receiving lercanidipine enter…

Pharmacologymedicine.medical_specialtyTriglyceridebusiness.industryLercanidipinemedicine.medical_treatmentUrologyEssential hypertensionmedicine.diseasechemistry.chemical_compoundHydrochlorothiazideEndocrinologychemistryInternal medicineHeart ratemedicinePharmacology (medical)DiureticbusinessThiazidemedicine.drugLipoproteinCurrent Therapeutic Research
researchProduct